• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2019年冠状病毒病首次爆发后平缓曲线:中国奥密克戎大流行的数据驱动建模分析

Flattening the Curve after the Initial Outbreak of Coronavirus Disease 2019: A Data-Driven Modeling Analysis for the Omicron Pandemic in China.

作者信息

Sun Jiaqi, Li Yusi, Xiao Lin-Fan, Shao Ning-Yi, Liu Miao

机构信息

Department of Mathematics, Faculty of Science and Technology, University of Macau, Taipa, Macau, China.

Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.

出版信息

Vaccines (Basel). 2023 May 22;11(5):1009. doi: 10.3390/vaccines11051009.

DOI:10.3390/vaccines11051009
PMID:37243113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10224169/
Abstract

China is relaxing COVID-19 measures from the "dynamic zero tolerance" (DZT) level. The "flatten-the-curve" (FTC) strategy, which decreases and maintains the low rate of infection to avoid overwhelming the healthcare system by adopting relaxed nonpharmaceutical interventions (NPIs) after the outbreak, has been perceived as the most appropriate and effective method in preventing the spread of the Omicron variant. Hence, we established an improved data-driven model of Omicron transmission based on the age-structured stochastic compartmental susceptible-latent-infectious-removed-susceptible model constructed by Cai to deduce the overall prevention effect throughout China. At the current level of immunity without the application of any NPIs, more than 1.27 billion (including asymptomatic individuals) were infected within 90 days. Moreover, the Omicron outbreak would result in 1.49 million deaths within 180 days. The application of FTC could decrease the number of deaths by 36.91% within 360 days. The strict implementation of FTC policy combined with completed vaccination and drug use, which only resulted in 0.19 million deaths in an age-stratified model, will help end the pandemic within about 240 days. The pandemic would be successfully controlled within a shorter period of time without a high fatality rate; therefore, the FTC policy could be strictly implemented through enhancement of immunity and drug use.

摘要

中国正在从“动态清零”水平放宽新冠疫情防控措施。“曲线平缓化”(FTC)策略,即在疫情爆发后通过采取宽松的非药物干预措施(NPIs)来降低并维持低感染率,以避免医疗系统不堪重负,已被视为预防奥密克戎变异株传播的最合适、最有效的方法。因此,我们基于蔡构建的年龄结构随机分区易感-潜伏-感染-康复-易感模型,建立了一个改进的数据驱动的奥密克戎传播模型,以推断全中国的总体预防效果。在当前未应用任何NPIs的免疫水平下,90天内超过12.7亿人(包括无症状感染者)被感染。此外,奥密克戎疫情在180天内将导致149万人死亡。应用FTC可在360天内将死亡人数减少36.91%。在年龄分层模型中,严格实施FTC政策并结合完成疫苗接种和药物使用,仅导致19万人死亡,这将有助于在约240天内结束疫情。疫情将在更短时间内得到成功控制,且不会出现高死亡率;因此,可通过增强免疫力和使用药物来严格实施FTC政策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a27/10224169/95aea2ae32da/vaccines-11-01009-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a27/10224169/5be0a5339ed1/vaccines-11-01009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a27/10224169/a2a7087f0b4f/vaccines-11-01009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a27/10224169/42c617f90a9f/vaccines-11-01009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a27/10224169/95aea2ae32da/vaccines-11-01009-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a27/10224169/5be0a5339ed1/vaccines-11-01009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a27/10224169/a2a7087f0b4f/vaccines-11-01009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a27/10224169/42c617f90a9f/vaccines-11-01009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a27/10224169/95aea2ae32da/vaccines-11-01009-g004.jpg

相似文献

1
Flattening the Curve after the Initial Outbreak of Coronavirus Disease 2019: A Data-Driven Modeling Analysis for the Omicron Pandemic in China.2019年冠状病毒病首次爆发后平缓曲线:中国奥密克戎大流行的数据驱动建模分析
Vaccines (Basel). 2023 May 22;11(5):1009. doi: 10.3390/vaccines11051009.
2
Impact of combination preventative interventions on hospitalization and death under the pandemic of SARS-CoV-2 Omicron variant in China.联合预防干预措施对中国新冠病毒奥密克戎变异株大流行期间住院率和死亡率的影响
J Med Virol. 2023 Jan;95(1):e28335. doi: 10.1002/jmv.28335.
3
Modeling transmission of SARS-CoV-2 Omicron in China.模拟 SARS-CoV-2 奥密克戎在中国的传播。
Nat Med. 2022 Jul;28(7):1468-1475. doi: 10.1038/s41591-022-01855-7. Epub 2022 May 10.
4
The impact of age structure and vaccine prioritization on COVID-19 in West Africa.年龄结构和疫苗优先级对西非地区新冠肺炎的影响。
Infect Dis Model. 2022 Dec;7(4):709-727. doi: 10.1016/j.idm.2022.08.006. Epub 2022 Sep 8.
5
Quantifying the rebound of influenza epidemics after the adjustment of zero-COVID policy in China.量化中国调整动态清零政策后流感疫情的反弹情况。
PNAS Nexus. 2023 May 4;2(5):pgad152. doi: 10.1093/pnasnexus/pgad152. eCollection 2023 May.
6
Tuberculosis结核病
7
Policy choices for Shanghai responding to challenges of Omicron.上海应对奥密克戎挑战的政策选择。
Front Public Health. 2022 Aug 9;10:927387. doi: 10.3389/fpubh.2022.927387. eCollection 2022.
8
A model simulation on the SARS-CoV-2 Omicron variant containment in Beijing, China.中国北京针对严重急性呼吸综合征冠状病毒2奥密克戎变异株防控的模型模拟。
Intell Med. 2023 Feb;3(1):10-15. doi: 10.1016/j.imed.2022.10.005. Epub 2022 Nov 21.
9
Multi-Faceted Analysis of COVID-19 Epidemic in Korea Considering Omicron Variant: Mathematical Modeling-Based Study.考虑奥密克戎变异株的韩国 COVID-19 疫情的多方面分析:基于数学模型的研究。
J Korean Med Sci. 2022 Jul 4;37(26):e209. doi: 10.3346/jkms.2022.37.e209.
10
Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis.中国上海动态清零策略控制 COVID-19 :成本效益分析。
J Infect Public Health. 2023 Jun;16(6):893-900. doi: 10.1016/j.jiph.2023.04.005. Epub 2023 Apr 11.

引用本文的文献

1
Global burden of benign prostatic hyperplasia in males aged 60-90 years from 1990 to 2019: results from the global burden of disease study 2019.2019 年全球疾病负担研究:1990 年至 2019 年 60-90 岁男性良性前列腺增生的全球负担。
BMC Urol. 2024 Sep 5;24(1):193. doi: 10.1186/s12894-024-01582-w.
2
Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019.基于 2019 年全球疾病负担研究的中、美良性前列腺增生负担比较。
World J Urol. 2023 Dec;41(12):3629-3634. doi: 10.1007/s00345-023-04658-8. Epub 2023 Oct 13.

本文引用的文献

1
Impact of combination preventative interventions on hospitalization and death under the pandemic of SARS-CoV-2 Omicron variant in China.联合预防干预措施对中国新冠病毒奥密克戎变异株大流行期间住院率和死亡率的影响
J Med Virol. 2023 Jan;95(1):e28335. doi: 10.1002/jmv.28335.
2
Assessing the feasibility of sustaining SARS-CoV-2 local containment in China in the era of highly transmissible variants.评估在高传播性变异株流行时期中国维持 SARS-CoV-2 局部控制的可行性。
BMC Med. 2022 Nov 15;20(1):442. doi: 10.1186/s12916-022-02640-6.
3
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5.
二价mRNA疫苗加强针可诱导针对奥密克戎谱系BA.2、BA.2.12.1、BA.2.75和BA.5的强大抗体免疫。
Cell Discov. 2022 Oct 11;8(1):108. doi: 10.1038/s41421-022-00473-4.
4
Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants.吸入型腺病毒载体 COVID-19 疫苗异源加强针产生了更多针对不同 SARS-CoV-2 变体的中和抗体。
Emerg Microbes Infect. 2022 Dec;11(1):2689-2697. doi: 10.1080/22221751.2022.2132881.
5
A Bivalent Omicron-Containing Booster Vaccine against Covid-19.二价含奥密克戎成分的新冠病毒加强疫苗。
N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16.
6
Projecting COVID-19 Mortality as States Relax Nonpharmacologic Interventions.预测各州放松非药物干预措施后的 COVID-19 死亡率。
JAMA Health Forum. 2022 Apr 1;3(4):e220760. doi: 10.1001/jamahealthforum.2022.0760. eCollection 2022 Apr.
7
The clinical and bioinformatics analysis for the role of antihypertension drugs on mortality among patients with hypertension hospitalized with COVID-19.COVID-19 住院高血压患者的降压药物与死亡率的临床和生物信息学分析。
J Med Virol. 2022 Oct;94(10):4727-4734. doi: 10.1002/jmv.27914. Epub 2022 Jun 16.
8
Clinical Characteristics of COVID-19 Patients Infected by the Omicron Variant of SARS-CoV-2.感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变异株的2019冠状病毒病(COVID-19)患者的临床特征
Front Med (Lausanne). 2022 May 9;9:912367. doi: 10.3389/fmed.2022.912367. eCollection 2022.
9
Modeling transmission of SARS-CoV-2 Omicron in China.模拟 SARS-CoV-2 奥密克戎在中国的传播。
Nat Med. 2022 Jul;28(7):1468-1475. doi: 10.1038/s41591-022-01855-7. Epub 2022 May 10.
10
SARS-CoV-2 Omicron variant: recent progress and future perspectives.SARS-CoV-2 奥密克戎变异株:最新进展与未来展望。
Signal Transduct Target Ther. 2022 Apr 28;7(1):141. doi: 10.1038/s41392-022-00997-x.